ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.74 and traded as high as $7.02. ImmuCell shares last traded at $6.65, with a volume of 10,965 shares traded.
ImmuCell Stock Performance
The firm has a market capitalization of $60.75 million, a P/E ratio of -95.99 and a beta of 0.30. The firm has a 50-day moving average price of $6.54 and a two-hundred day moving average price of $5.75. The company has a debt-to-equity ratio of 0.30, a current ratio of 4.12 and a quick ratio of 2.21.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%.
Institutional Trading of ImmuCell
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock worth $500,000 after purchasing an additional 2,907 shares in the last quarter. Northern Trust Corp increased its holdings in shares of ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of ImmuCell during the fourth quarter valued at about $149,000. Finally, Dauntless Investment Group LLC acquired a new position in shares of ImmuCell during the fourth quarter valued at about $676,000. 13.47% of the stock is currently owned by institutional investors.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Articles
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access